PCI
Packaging Coordinators, Inc. (PCI) has introduced refrigerated GMP packaging for temperature-controlled pharmaceuticals at its site in the UK.
It is widely recognised that more and more temperature-sensitive investigational drug products have limited stability data available and as such there is an increasing need for projects to be labelled and packed within a refrigerated environment to maintain the drugs’ efficacy.
PCI is focussed on the rapidly changing needs of the clinical trial industry and responding to increased customer demand for specialised temperature controlled packaging and has introduced a dedicated capability for 2–8˚C packaging at its site in Hay-on-Wye.
“The safety of our customers’ products is of upmost importance to us,” stated Tim Roberts, Associate Director of Clinical Services, “By introducing this additional service, we will not only be able to ensure the safety and integrity of our customers’ products, we will help make significant efficiencies to their packaging lead times of temperature sensitive material.”
PCI has invested significantly in supporting cold chain logistics for packaging both investigational as well as commercial medicinal products in a variety of drug delivery forms, including oral solids and parenteral delivery forms such as injectable and transdermal. PCI’s global network of 14 locations features designated sites with specialised capabilities such as cold chain packaging, in addition to significant on-site cold chain storage at 2–8˚C, -20˚C, -40˚C and -80˚C.
PCI also supports controlled temperature shipments to worldwide investigational sites through its logistics network, which includes the recently announced construction of a new storage and distribution site for investigational medicines in North America, opening in August of this year.
Packaging Coordinators Inc., +44 1497 820829, www.pciservices.com.